Indivior (NASDAQ:INDV) Shares Gap Up – Time to Buy?

Indivior PLC (NASDAQ:INDV)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $12.18, but opened at $12.54. Indivior shares last traded at $12.56, with a volume of 21,575 shares traded.

Analysts Set New Price Targets

INDV has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum cut their price objective on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Indivior Stock Performance

The company has a market cap of $1.71 billion, a P/E ratio of -310.67 and a beta of 0.75. The business has a 50 day moving average price of $10.84 and a two-hundred day moving average price of $11.43. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.65 and a current ratio of 0.83.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. On average, sell-side analysts anticipate that Indivior PLC will post 1.68 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

A number of large investors have recently added to or reduced their stakes in INDV. Stifel Financial Corp purchased a new stake in shares of Indivior during the third quarter worth about $100,000. Melqart Asset Management UK Ltd bought a new position in Indivior during the 3rd quarter valued at approximately $132,000. Jane Street Group LLC purchased a new stake in Indivior in the 3rd quarter worth approximately $180,000. Bank of New York Mellon Corp bought a new stake in shares of Indivior in the 2nd quarter worth approximately $188,000. Finally, VELA Investment Management LLC purchased a new position in shares of Indivior during the second quarter valued at approximately $235,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.